NewsRoom Articles

ThursdaySep 12, 2024 10:00 am

California Governor Announces Emergency Regulations Banning THC-Infused Hemp Products

Governor Gavin Newsom of California recently issued emergency regulations to protect children in the state from the adverse health effects of THC-infused hemp products. The state of California was the first in the country to allow the medical use of marijuana when voters approved the Compassionate Use Act. In 2016, voters in the state then passed a measure that legalized the recreational use of marijuana. Gov. Newsom announced that the state was taking action to close loopholes and increase enforcement to prevent children from gaining access to these dangerous hemp products. The state’s marijuana industry is strictly regulated to ensure…

TuesdaySep 10, 2024 10:00 am

VW Announces Project to Replace Leather Car Interior Materials with Hemp Alternatives

Earlier this week, Volkswagen announced that it would be working with Revoltech GmbH to produce a leather alternative for its vehicles. Revoltech manufactures leather from hemp, making its products 100% plant-based, as well as plastic free and sustainable. The German automobile manufacturer made this announcement just months after the cannabis legalization law took effect in Germany. The industrial hemp to be used will be sourced from farms in the region, with Volkswagen noting that the material will be made from hemp residues that cultivators have no use for. In the press release, Kai Grünitz, a board member at VW, revealed…

ThursdaySep 05, 2024 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study

Lexaria, a global innovator in drug delivery platforms, has just announced its 4-week and 8-week blood glucose results from its WEIGHT-A24-1 animal study Two formulations from the study posted outstanding performance, with each utilizing the company’s patented DehydraTECH(TM) technology DehydraTECH-liraglutide (Group H) and two DehydraTECH-CBD formulations (Groups A & B) posted blood sugar level reductions of 2.50%, 1.90%, and 1.53%, respectively These results build on the positive results from Lexaria’s 2023 DIAB-A22-1 animal study, which showed a 16.7% blood sugar concentration increase relative to baseline by day 56 for the obese control group that got no treatment Lexaria Bioscience (NASDAQ:…

ThursdaySep 05, 2024 10:00 am

Missouri Hemp Trade Association Sues to Block Governor’s Ban of THC Drinks, Foods

Last month, Governor Mike Parson of Missouri signed an executive order that would remove all THC drinks and edibles derived from hemp from shelves and impose penalties on any establishment that continued to sell them. In his statement, Parson stated that the primary target of his order were companies that sold intoxicating hemp edibles mimicking candy. He explained that because hemp wasn’t a controlled substance, there were no federal or state laws prohibiting minors from purchasing these products or even preventing stores from selling the products to underaged individuals. Last week, the state’s Hemp Trade Association filed a suit in…

TuesdaySep 03, 2024 10:00 am

Proposed Georgia CBD Law Seeks to Cap Delta-9 THC

A new law introduced in Georgia will help rein in the state’s burgeoning legal hemp industry. The law, which goes into effect on Oct. 1, 2024, may change the way consumers consume CBD drinks and edibles such as gummies. While medical cannabis is heavily regulated in the state, legal variations of marijuana including delta-9 THC products have become very popular. The new law makes the legal age to consume marijuana 21, creates registration and testing requirements, and imposes a limit on the amount of delta-9 THC allowed in products. Under the new rules, the sale of hemp flower would be…

ThursdayAug 29, 2024 10:30 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-901: A Promising New Candidate for Alzheimer’s Therapy

INM-901 oral formulation shows encouraging results in preclinical studies High bioavailability of INM-901 oral formulation was shown to provide similar drug concentration levels in the brain as intraperitoneal injection Oral delivery method offers advantages such as lower treatment costs, in comparison with intravenous delivery of large molecule antibody therapies The company is conducting further research including drug metabolism studies, dose ranging studies and pharmacokinetic studies InMed Pharmaceuticals (NASDAQ: INM), a clinical stage pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates targeting the CB1/CB2 receptors, announced that its drug candidate INM-901 as an oral formulation will…

ThursdayAug 29, 2024 10:00 am

Medical Marijuana, Intoxicating Hemp Products Go Head to Head in Mississippi

In 2020, 69% of voters in the state of Mississippi passed a medical cannabis initiative, but the Supreme Court of the state nullified the measure. Two years later, the legislature approved the Mississippi Medical Cannabis Act, allowing the establishment of a high-quality, regulated industry. Less than a year later, more than 20,000 residents in the state were benefitting from the program. Medical cannabis production in the state is strictly regulated, with all growers having to apply for permits before they can commence their operations. Every plant is also tracked from the time it hits six inches in height through maturity…

TuesdayAug 27, 2024 10:00 am

Businesses Complain That Illicit Hemp Intoxicants Undercut Medical Cannabis

Earlier this week, the Medical Marijuana Oversight Committee in South Dakota held a meeting during which the state’s director of Public Health Laboratory along with business owners discussed how illegal hemp intoxicants were affecting the state’s medical cannabis industry. In particular, these parties are concerned about the proliferation of synthetically modified products derived from hemp and are being sold as delta-8 and delta-10 THC. These compounds induce a high similar to cannabis. Similar to cannabis, these synthetic products are in form of pre-rolled joints, smokable flower, edibles and vape oil. Unlike cannabis, however, the companies that produce these products aren’t…

MondayAug 26, 2024 12:00 pm

Lexaria Bioscience Corp. (NASDAQ: LEXX) Validates Technology’s Superiority, Moving Closer to a Share in the Global Diabetes Treatment Market

Lexaria, a global innovator in drug delivery platforms, just reported positive results from its applied research program conducted in collaboration with the National Research Council of Canada (“NRC”) The study’s objective was to examine the molecular properties of semaglutide, processed with its patented DehydraTECH(TM) technology, comparing it to Rybelsus(R), the commercially available alternative Lexaria’s DehydraTECH demonstrated that semaglutide can be efficiently released in a simulated gastric fluid environment, without the use of salcaprozate sodium (“SNAC”) ingredient chemistry This milestone moves the company closer to the diabetes treatment market, projected to hit $153.98 billion in value by 2032 Lexaria Bioscience (NASDAQ:…

MondayAug 26, 2024 9:00 am

InMed Pharmaceuticals Inc. (NASDAQ: INM) Reports Promising Long-Term Results for Alzheimer’s Drug INM-901

A long-term preclinical study of Alzheimer's Disease (“AD”) drug candidate INM-901 included four groups: untreated disease-free, INM-901-treated disease-free, placebo-treated Alzheimer's Disease, and INM-901-treated Alzheimer's Disease at two dosing levels The results showed that INM-901-treated AD groups displayed behavior trends similar to the untreated disease-free group, with a clear dose response observed in most assessments The drug has also shown a reduction in neuroinflammation and enhancement of neuronal function, with molecular data supporting behavioral study observations InMed Pharmaceuticals (NASDAQ: INM), a biopharmaceutical company focused on developing proprietary small molecule drug candidates for diseases with high unmet needs, has announced promising outcomes…

News and publishing service for hemp related companies

Contact us: 303.498.7722